Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies
Phase 1 Withdrawn
Neo-Kan
Phase 2 Withdrawn
Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung
Phase 1 Withdrawn
Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer
Phase 2 Withdrawn
Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation
Phase 1 Withdrawn
ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck
Phase 1 Withdrawn
Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers
Phase 1/2 Withdrawn
Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide
Phase 1 Withdrawn
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
Phase 2 Withdrawn
CERAD-IMMUNE
Phase 2 Withdrawn
Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer
Phase 2 Withdrawn
Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study
Phase 1/2 Withdrawn
A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
Phase 2 Withdrawn
IMMUNOX
Phase 2 Withdrawn
Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy
Phase 2 Withdrawn
SBRT as a Vaccination for Metastatic Melanoma
Phase 2 Withdrawn
Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
Phase 1/2 Withdrawn
MicroBLITZ
Phase 1 Withdrawn
Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.
Phase 2 Withdrawn
Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma
Phase 1 Withdrawn
BENEFIT
Phase 1 Withdrawn
Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia
Phase 1 Withdrawn
Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma
Phase 2 Withdrawn
PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer
Phase 1/2 Withdrawn
PPD1
Phase 1 Withdrawn
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
Phase 2 Withdrawn
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
Phase 2/3 Withdrawn
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
Phase 2 Withdrawn
Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung
Phase 1/2 Withdrawn
Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
Phase 1 Withdrawn
Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors
Phase 2 Withdrawn
Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 1 Withdrawn
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
Phase 2 Withdrawn
Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
Phase 2 Withdrawn
Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads
Phase 2 Withdrawn
Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
Phase 2 Withdrawn
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
Phase 1/2 Withdrawn
Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
Phase 1 Withdrawn
Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas
Phase 2 Withdrawn
Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Withdrawn
A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
Phase 2 Withdrawn
Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib
Phase 1 Withdrawn